IRD insider ownership: who sold, why, and what they still hold

What stands out

Cam Gallagher bought 81K shares for $160K, first on Dec 29, 2025.Purchase, Dec 29, 2025

Tax withholding outweighed market sales: the company withheld $600K of officers' and directors' shares for taxes, against $596K sold on the open market. The largest was George Magrath ($521K withheld).Largest withholding, Sep 9, 2026

A share of stake is shown for 0 of the 6 officers and directors who sold. 13 are left out

Left out: Cam Gallagher, George Magrath, Benjamin Yerxa, Richard Rodgers, James Manuso, Sean Ainsworth, Susan Benton, Jean Bennett, Robert Gagnon, Ashwath Jayagopal, Rabourn Zaremba, Adrienne Graves and Joseph Schachle (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

George Magrath

Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$205KTo cover taxes

Robert Gagnon

Chief Financial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$191K67% planned, 33% to cover taxes

Benjamin Yerxa

President, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$61KTo cover taxes

Ashwath Jayagopal

Chief Scientific & Dev. Ofc.

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$58KTo cover taxes

Joseph Schachle

Chief Operating Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$58KTo cover taxes

All 6 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 17, 2026 to Oct 16, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Sep 9, 2026George Magrath had 76K shares ($451K) withheld by the company for taxes (not a market sale). 392K shares came in from vesting or option exercises the same day, so the holding rose by 317K net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
George Magrath Chief Executive Officer, Director	75,541	$5.97	n/a	n/a	Sep 9, 2026	Sep 11, 2026

Outside holders, reported separately

Foundation Fighting Blindness Retinal Degeneration Fund sold $18.8M in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Opus Genetics, Inc. CEO selling stock?

Yes. George Magrath sold 43K shares ($205K) in the past 12 months, none of it under a trading plan disclosed in the filings.

Why are Opus Genetics, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 21% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 79% were to cover taxes. A trading plan schedules sales in advance.

Are any Opus Genetics, Inc. insiders buying?

Yes. 1 officer or director reported 1 purchase in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

The evidence

Who sold6 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
George Magrath Chief Executive Officer, Director	$205K 43K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Robert Gagnon Chief Financial Officer	$191K 44K shares	Not confirmed share of stake is being verified. Why	67% under a disclosed plan, 33% to cover taxes
Benjamin Yerxa President, Director	$61K 15K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Ashwath Jayagopal Chief Scientific & Dev. Ofc.	$58K 11K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Joseph Schachle Chief Operating Officer	$58K 13K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Rabourn Zaremba Head of Fin. Quality Assurance	$23K 4.5K shares	Not confirmed share of stake is being verified. Why	To cover taxes

Outside holder, reported separately: Foundation Fighting Blindness Retinal Degeneration Fund (an outside shareholder, not part of management). Sold $18.8M (6.26M shares) from Dec 9, 2025 to Sep 30, 2026. Latest filing

The full ownership picture0 of 13 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 16, 2025

Sold

Held Oct 16, 2026

Still held

Cam Gallagher

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Cam Gallagher are complete.

Director

n/a

Vesting, gifts, unvested awards and holding lines for Cam Gallagher

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Cam Gallagher are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
35,181	$1.72	Jun 10, 2034	$114K
79,592	$0.95	Apr 29, 2035	$319K

Estimate: options held × ($4.96 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

George Magrath

Chief Executive Officer, Director

n/a

−43K

n/a

Vesting, gifts, unvested awards and holding lines for George Magrath

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for George Magrath are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−106Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
600,000	$2.87	Oct 31, 2033	$1.3M
330,697	$0.93	Mar 12, 2035	$1.3M

Estimate: options held × ($4.96 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Benjamin Yerxa

President, Director

n/a

−15K

n/a

Vesting, gifts, unvested awards and holding lines for Benjamin Yerxa

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Benjamin Yerxa are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−24Kwithheld by the company for taxes

Richard Rodgers

Director

n/a

Vesting, gifts, unvested awards and holding lines for Richard Rodgers

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Richard Rodgers are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
35,181	$1.72	Jun 10, 2034	$114K
79,592	$0.95	Apr 29, 2035	$319K

Estimate: options held × ($4.96 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

James Manuso

Director

n/a

Vesting, gifts, unvested awards and holding lines for James Manuso

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for James Manuso are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
35,181	$1.72	Jun 10, 2034	$114K
79,592	$0.95	Apr 29, 2035	$319K

Estimate: options held × ($4.96 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Sean Ainsworth

Director

n/a

Vesting, gifts, unvested awards and holding lines for Sean Ainsworth

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sean Ainsworth are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
35,181	$1.72	Jun 10, 2034	$114K
79,592	$0.95	Apr 29, 2035	$319K

Estimate: options held × ($4.96 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Susan Benton

Director

n/a

Vesting, gifts, unvested awards and holding lines for Susan Benton

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Susan Benton are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
35,181	$1.72	Jun 10, 2034	$114K
79,592	$0.95	Apr 29, 2035	$319K

Estimate: options held × ($4.96 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Jean Bennett

Director

n/a

Vesting, gifts, unvested awards and holding lines for Jean Bennett

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jean Bennett are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
172,874	$1.33	Oct 21, 2034	$627K
79,592	$0.95	Apr 29, 2035	$319K

Estimate: options held × ($4.96 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Robert Gagnon

Chief Financial Officer

n/a

−44K

n/a

Vesting, gifts, unvested awards and holding lines for Robert Gagnon

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Robert Gagnon are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
250,000	$1.23	Sep 1, 2035	$932K

Estimate: options held × ($4.96 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Ashwath Jayagopal

Chief Scientific & Dev. Ofc.

n/a

−11K

n/a

Vesting, gifts, unvested awards and holding lines for Ashwath Jayagopal

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ashwath Jayagopal are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−5.3Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
225,000	$2.66	Feb 11, 2034	$517K
52,500	$0.93	Mar 12, 2035	$211K

Estimate: options held × ($4.96 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Rabourn Zaremba

Head of Fin. Quality Assurance

n/a

−4.5K

n/a

Vesting, gifts, unvested awards and holding lines for Rabourn Zaremba

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Rabourn Zaremba are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−7.3Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
60,000	$2.77	Jan 17, 2034	$131K
39,500	$0.93	Mar 12, 2035	$159K

Estimate: options held × ($4.96 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Adrienne Graves

Director

n/a

Vesting, gifts, unvested awards and holding lines for Adrienne Graves

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Adrienne Graves are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
172,874	$1.33	Oct 21, 2034	$627K
79,592	$0.95	Apr 29, 2035	$319K

Estimate: options held × ($4.96 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Joseph Schachle

Chief Operating Officer

n/a

−13K

n/a

Vesting, gifts, unvested awards and holding lines for Joseph Schachle

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Joseph Schachle are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
300,000	$2.79	Nov 26, 2033	$650K
52,500	$0.93	Mar 12, 2035	$211K

Estimate: options held × ($4.96 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Holdings and share of stake for Opus Genetics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$596K of sales by plan status, purpose, seller and month

Officer and director open-market sales: $596K across 130,726 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $127K · 21%

79%

The lighter segment is sales with no plan disclosed in the filing ($469K), including tax-related sales outside a plan.

Taxes

$596K of sales (100.0%) cite tax obligations in their footnotes, $127K of them also under a plan. Separately, 142,339 shares ($600K) were withheld by the company for taxes, which isn't a market sale. Example: Robert Gagnon, Sep 3, 2026

Purchases · 1 buyer (1 trade)

1 officer or director bought shares in this period, in 1 trade(Form 4 code P, leaving out rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust). Across all their filings on record there are 12 purchase trades.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
George Magrath Chief Executive Officer, Director	43K	$205K	0%	34%	Mar 16, 2026 to Jul 23, 2026
Robert Gagnon Chief Financial Officer	44K	$191K	67%	32%	Apr 23, 2026 to Sep 3, 2026
Benjamin Yerxa President, Director	15K	$61K	0%	10%	Apr 23, 2026 to Jul 23, 2026
Ashwath Jayagopal Chief Scientific & Dev. Ofc.	11K	$58K	0%	10%	Mar 16, 2026 to Apr 23, 2026
Joseph Schachle Chief Operating Officer	13K	$58K	0%	10%	Mar 16, 2026 to Jul 23, 2026
Rabourn Zaremba Head of Fin. Quality Assurance	4.5K	$23K	0%	4%	Mar 16, 2026 to Apr 23, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$0	$0	$0	$0
Dec 2025	$0	$0	$0	$0
Jan 2026	$0	$0	$0	$0
Feb 2026	$0	$0	$0	$0
Mar 2026	$181K	$0	$181K	$0
Apr 2026	$202K	$0	$202K	$0
May 2026	$0	$0	$0	$0
Jun 2026	$0	$0	$0	$0
Jul 2026	$87K	$0	$87K	$0
Aug 2026	$0	$0	$0	$0
Sep 2026	$127K	$127K	$0	$0
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

Unusual for this company: officers and directors sold shares for the first time in 6 years. 6 insiders sold; the average is 0 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 16, 2026 Latest 12 months	131K	6	$596K
Oct 16, 2025 1 year earlier	0	0	$0
Oct 16, 2024 2 years earlier	0	0	$0
Oct 17, 2023 3 years earlier	0	0	$0
Oct 17, 2022 4 years earlier	0	0	$0
Oct 17, 2021 5 years earlier	0	0	$0

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty13 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Opus Genetics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology398 filings on record, 45 filed in the 12-month period, and how we read them

All 398 Forms 3, 4 and 5 on record for Opus Genetics, Inc. (SEC CIK 1228627), filed from Aug 18, 2004 to Oct 2, 2026; 45 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages.

Probable 1-for-10 stock split on or before Aug 16, 2017 (first filing that shows post-split balances). Splits aren't reported as transactions; 2 holding lines changed by exactly this ratio, so earlier share counts are restated.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (36)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Bernhard Hoffmann	Mar 17, 2025	185,446 shares, last reported balance as of Mar 13, 2025
Nirav Jhaveri	Mar 17, 2025	194,293 shares, last reported balance as of Mar 13, 2025
Jay Pepose	Jun 13, 2024	180,458 shares, last reported balance as of Jun 11, 2024
Ronil Patel	Jan 12, 2024	90,714 shares, last reported balance as of Jan 10, 2024
Mina Sooch	Feb 14, 2023	480,501 shares, last reported balance as of Jan 10, 2023
Alan Meyer	Nov 25, 2020	487,029 shares, last reported balance as of Nov 19, 2020
Charles Beever	Jun 7, 2019	11,000 shares, last reported balance as of Jan 31, 2019
Kwang Cheong	Jun 7, 2019	300 shares, last reported balance as of Jun 11, 2013
Peter Brandt	Jun 7, 2019	15,000 shares, last reported balance as of Jun 11, 2013
Ben Price	Jun 7, 2019	15,000 shares, last reported balance as of Jan 29, 2019
Lara Sullivan	Jun 7, 2019	No balance on record
Ely Benaim	Mar 1, 2019	4,750 shares, last reported balance as of Feb 28, 2019
Lisa Nolan	Mar 1, 2019	23,250 shares, last reported balance as of Feb 28, 2019
Douglas Swirsky	Jan 30, 2019	50,000 shares, last reported balance as of Jan 29, 2019
Peter Suzdak	Mar 2, 2018	22,250 shares, last reported balance as of Feb 28, 2018
Chang Ahn	Apr 12, 2017	701,000 shares, last reported balance as of Apr 10, 2017
Mark Carthy	Apr 12, 2017	No balance on record
Chang Ahn	Apr 12, 2017	400,000 shares, last reported balance as of Dec 20, 2011
Tae Jeong	Jan 24, 2017	51,000 shares, last reported balance as of Jan 12, 2015
David McIntosh	Jun 11, 2014	3,159 shares, last reported balance as of Apr 14, 2014
Si Hwang	Jun 11, 2014	36,220 shares, last reported balance as of Jun 11, 2013
Rakesh Soni	Jan 14, 2014	270 shares, last reported balance as of Jan 12, 2014
Richard Kivel	Jun 20, 2012	250 shares, last reported balance as of Jun 18, 2012
Michele Kang	Jun 2, 2009	1,000 shares, last reported balance as of Apr 24, 2008
Freddie Hoffman	Jun 2, 2009	100 shares, last reported balance as of Apr 14, 2008
Rexgene Biotech Co., Ltd.	Dec 26, 2007	1,029,763 shares, last reported balance as of Dec 24, 2007
Young Park	Jan 8, 2007	270,650 shares, last reported balance as of Dec 11, 2006
Inok Ahn	May 5, 2006	1,400,000 shares, last reported balance as of May 13, 2005
John Holaday	May 4, 2006	No balance on record
George Steinfels	May 3, 2006	No balance on record
Suk Kwon	May 17, 2005	221,026 shares, last reported balance as of May 13, 2005
Jang Rhee	May 17, 2005	200,000 shares, last reported balance as of May 13, 2005
Korean Rexahn Investors Voting Trust	May 17, 2005	No balance on record
Sung-Kee Chung	Jan 21, 2005	16,380,000 shares, last reported balance as of Jan 11, 2005
Sung Park	Jan 21, 2005	7,020,000 shares, last reported balance as of Jan 11, 2005
Frank Ferraro	Jan 13, 2005	2,600,000 shares, last reported balance as of Jan 11, 2005

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Opus Genetics, Inc. insiders sold $596K in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Opus Genetics, Inc. CEO selling stock?

Why are Opus Genetics, Inc. insiders selling?

Are any Opus Genetics, Inc. insiders buying?

The evidence

Taxes

Purchases · 1 buyer (1 trade)

Sales by month